| human | Q5 |
| P6178 | Dimensions author ID | 01223762727.50 |
| P856 | official website | https://pureprojects.ppad.man.ac.uk/portal/en/researchers/paul-lorigan(d695629b-4405-4455-9a26-aaf14c721b6c).html |
| https://www.research.manchester.ac.uk/portal/paul.c.lorigan.html | ||
| P496 | ORCID iD | 0000-0002-8875-2164 |
| P3829 | Publons author ID | 2376045 |
| P1053 | ResearcherID | J-6898-2015 |
| P1153 | Scopus author ID | 6604053967 |
| P10861 | Springer Nature person ID | 01223762727.50 |
| P69 | educated at | Trinity College Dublin | Q258464 |
| P108 | employer | University of Manchester | Q230899 |
| The Christie NHS Foundation Trust | Q5110676 | ||
| Royal Lancaster Infirmary | Q14956805 | ||
| Respond! | Q17092713 | ||
| Wythenshawe Hospital | Q29131372 | ||
| P734 | family name | Lorigan | Q37549097 |
| Lorigan | Q37549097 | ||
| Lorigan | Q37549097 | ||
| P735 | given name | Paul | Q4925623 |
| Paul | Q4925623 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q57569459 | 25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial |
| Q57569719 | 35 CONVERT-A multicentre randomised controlled NCRN trial comparing accelerated twice-daily and high dose once-daily thoracic radiotherapy in good performance status (PS), limited small-cell lung cancer (LD SCLC) treated concurrently with cisplatin a |
| Q57569710 | 510 POSTER Phase I study of IMGN901 (BB-10901) in patients with CD56-positive solid tumours |
| Q36674146 | A Guideline for the Management of Gastrointestinal Stromal Tumour (GIST). |
| Q57569728 | A Review of the Treatment Strategies for Small Cell Lung Carcinoma Patients with a Poor Performance Status |
| Q33394173 | A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours |
| Q57569610 | A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation |
| Q33367359 | A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer. |
| Q57569726 | A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology |
| Q43572875 | A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre |
| Q45744880 | A qualitative exploration of a respiratory distress symptom cluster in lung cancer: cough, breathlessness and fatigue |
| Q39690446 | A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update |
| Q33414272 | A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. |
| Q57569591 | Abstract 3704: Novel panRAF inhibitors active in melanomas that are resistant to BRAF-selective, or BRAF-selective/MEK inhibitor combinations |
| Q57569594 | Abstract CT331: Phase I/II trial of a novel antibody DNA immunotherapy, targeting CD64, in the treatment of Melanoma |
| Q58591344 | Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries |
| Q52586819 | Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. |
| Q92727463 | Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial |
| Q57569466 | Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial |
| Q52839795 | Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. |
| Q51012672 | Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. |
| Q38686174 | Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis |
| Q38068205 | Advances in the management of melanoma: targeted therapy, immunotherapy and future directions |
| Q44796056 | Advances in the treatment of late stage melanoma |
| Q90721837 | An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system |
| Q57569638 | Anti-Angiogenesis Therapy for Melanoma |
| Q48579036 | Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient |
| Q92890473 | Anti-PD1 treatment of advanced melanoma: development of criteria for a safe stop |
| Q53803543 | Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. |
| Q57423025 | Applying Best–Worst scaling methodology to establish delivery preferences of a symptom supportive care intervention in patients with lung cancer |
| Q39134793 | Assessing the impact of diagnosis and the related supportive care needs in patients with cutaneous melanoma. |
| Q92373122 | Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial |
| Q36723231 | Asthma in pregnancy complicated by iatrogenic pulmonary oedema. |
| Q56828346 | Authors' reply to Bayley and Cave |
| Q50043910 | Autoimmune fasciitis triggered by the anti-programmed cell death-1 monoclonal antibody nivolumab |
| Q44456291 | BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling |
| Q43436700 | Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin |
| Q54318225 | Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. |
| Q46488979 | Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma |
| Q38845362 | Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection? |
| Q34510816 | Characteristics of women with recurrent molar pregnancies. |
| Q34585566 | Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients |
| Q40443797 | Chemotherapy with vincristine/ifosfamide/carboplatin/etoposide in small cell lung cancer |
| Q48522100 | Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma. |
| Q38218425 | Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance |
| Q57569666 | Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine |
| Q41380574 | Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial |
| Q57423026 | Considerations in developing and delivering a non-pharmacological intervention for symptom management in lung cancer: the views of health care professionals |
| Q47657297 | Considerations in developing and delivering a nonpharmacological intervention for symptom management in lung cancer: the views of patients and informal caregivers |
| Q55022893 | Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma. |
| Q36081891 | Continuous infusion of 5-fluorouracil with alpha 2b interferon for advanced colorectal carcinoma |
| Q36622678 | Copy number gain at 12q12-14 may be important in the transformation from follicular lymphoma to diffuse large B cell lymphoma |
| Q62674217 | Corrigendum to “Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*” [Eur J Cancer 91 (2018) 116–124] |
| Q112638928 | Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma |
| Q91775923 | Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer |
| Q41032444 | Current drug treatment guidelines for epithelial ovarian cancer |
| Q93062435 | Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement |
| Q54375138 | DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. |
| Q64986104 | Dabrafenib and its use in the treatment of metastatic melanoma. |
| Q38953272 | Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery |
| Q37281253 | Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA. |
| Q57569716 | Does Adjuvant Vaccine Therapy Really Have Activity in Malignant Melanoma? |
| Q50074715 | Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis |
| Q57569724 | Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer |
| Q47937657 | Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study). |
| Q39038191 | Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis |
| Q46572104 | Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). |
| Q36898404 | Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy |
| Q92850105 | Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma |
| Q53141706 | Efficacy of positron emission tomography staging for small-cell lung cancer: a systematic review and cost analysis in the Australian setting. |
| Q46009188 | Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. |
| Q57796241 | Emergency management of immune-related hypophysitis: Collaboration between specialists is essential to achieve optimal outcomes |
| Q64113599 | Enhanced Fatty Acid Scavenging and Glycerophospholipid Metabolism Accompany Melanocyte Neoplasia Progression in Zebrafish |
| Q37142504 | Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR |
| Q37278502 | Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy |
| Q46423592 | Expanded access programmes: patient interests versus clinical trial integrity |
| Q57569694 | Extensive-stage small-cell lung cancer--moving beyond response rate? |
| Q40607948 | Fatal pulmonary fibrosis associated with induction chemotherapy with carboplatin and vinorelbine followed by CHART radiotherapy for locally advanced non-small cell lung cancer |
| Q43147493 | Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. |
| Q34361938 | Gender and survival in malignant tumours. |
| Q57569815 | Gestational choriocarcinoma of the ovary diagnosed by analysis of tumour DNA |
| Q46899890 | Guidelines for the stratification of patients recruited to trials of therapy for low-risk gestational trophoblastic tumor |
| Q36185580 | Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment |
| Q36615318 | High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia |
| Q91323283 | High-risk cutaneous melanoma follow-up: time for more intensive surveillance? |
| Q41681016 | Hyponatraemia secondary to nivolumab-induced primary adrenal failure. |
| Q38457830 | Identification of novel regions of amplification and deletion within mantle cell lymphoma DNA by comparative genomic hybridization |
| Q56828360 | Identifying melanomas in primary care: can we do better? |
| Q89943358 | Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy |
| Q50203119 | Immunotherapy: Does adjuvant ipilimumab have little adverse effect on quality of life? |
| Q27861062 | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma |
| Q27853091 | Improved overall survival in melanoma with combined dabrafenib and trametinib |
| Q24631953 | Improved survival with vemurafenib in melanoma with BRAF V600E mutation |
| Q57569675 | Improving Survival with Thoracic Radiotherapy in Patients with Small Cell Lung Cancer. The CONVERT and the REST Trials |
| Q28244235 | Improving outcomes in advanced malignant melanoma: update on systemic therapy |
| Q37660341 | Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma |
| Q49061471 | Integrating radiation therapy with emerging systemic therapies: Lessons from a patient with cerebral radionecrosis, spinal cord myelopathy, and radiation pneumonitis. |
| Q36620606 | Investigation of female survival benefit in metastatic melanoma |
| Q36028546 | Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients |
| Q57569586 | LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY |
| Q45349601 | Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. |
| Q99568575 | Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial |
| Q53559619 | Low-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue. |
| Q36274388 | Lung cancer after treatment for Hodgkin's lymphoma: a systematic review |
| Q37764474 | Lung cancer after treatment for breast cancer |
| Q54168407 | MDR-1 expression in non-Hodgkin's lymphomas is unrelated to treatment intensity or response to therapy. |
| Q57569473 | Management of Chronic Hypotony following Bilateral Uveitis in a Patient Treated with Pembrolizumab for Cutaneous Metastatic Melanoma |
| Q37987205 | Management of small cell lung cancer: recent developments for optimal care |
| Q36164374 | Management of small-cell lung cancer |
| Q57569684 | Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008 |
| Q28553228 | Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015 |
| Q44224877 | Melanoma cell attachment, invasion, and integrin expression is upregulated by tumor necrosis factor alpha and suppressed by alpha melanocyte stimulating hormone |
| Q55041730 | Melanoma vaccines--they should work. |
| Q36967155 | Modern management of small-cell lung cancer |
| Q44063168 | Monitoring tumour cells in the peripheral blood of small cell lung cancer patients |
| Q39195305 | Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells |
| Q33421351 | Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. |
| Q38245356 | No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients |
| Q36651648 | Novel therapies for the treatment of small-cell lung cancer: a time for cautious optimism? |
| Q37177925 | O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib |
| Q57569738 | O-095 A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small cell lung cancer — A randomised multicentre trial of the British thoracic |
| Q57569748 | O-153 Phase III randomised trial of doxorubicin based chemotherapy compared with platinum based chemotherapy in both limited and extensive stage patients |
| Q57569783 | Oestrogenic Steroids and Melanoma Cell Interaction with Adjacent Skin Cells Influence Invasion of Melanoma Cells In Vitro |
| Q44390796 | Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial |
| Q50969350 | Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy. |
| Q39827211 | Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis |
| Q46394566 | Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. |
| Q57569550 | PD-L1 expression as a potential predictive biomarker |
| Q35749833 | Palliative treatment |
| Q57569509 | Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma |
| Q34978580 | Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma |
| Q50198949 | Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial. |
| Q38617638 | Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). |
| Q92182785 | Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study |
| Q36817105 | Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial |
| Q33332278 | Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease. |
| Q40279253 | Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease |
| Q36879421 | Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors |
| Q37182228 | Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma |
| Q57569597 | Phase II Pilot Study of Intravenous High-Dose Interferon With or Without Maintenance Treatment in Melanoma at High Risk of Recurrence |
| Q34554316 | Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial |
| Q36611765 | Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer |
| Q33389113 | Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer |
| Q37340395 | Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma |
| Q57569687 | Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer |
| Q37677908 | Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma |
| Q51616377 | Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. |
| Q57569718 | Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Stud |
| Q36858092 | Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer |
| Q34647109 | Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma |
| Q33386055 | Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer |
| Q49317428 | Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients |
| Q57569751 | Platinum-based chemotherapy with thoracic radiotherapy in stage III good performance status non-small cell lung cancer patients |
| Q33385176 | Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells |
| Q92152629 | Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA |
| Q39150242 | Prevalence and correlates of unmet supportive care needs in patients with resected invasive cutaneous melanoma |
| Q57569583 | Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma |
| Q57569698 | Prise en charge du cancer bronchique à petites cellules (CPC) (localisé et étendu) |
| Q92754668 | Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma |
| Q36526895 | Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with lim |
| Q36431395 | Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate |
| Q37233861 | Radiotherapy for small-cell lung cancer-Where are we heading? |
| Q57569689 | Radiotherapy in Extensive-disease Small Cell Lung Cancer. A Survey of Current UK Practice |
| Q33395837 | Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062. |
| Q33394001 | Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group |
| Q40578614 | Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma |
| Q45267156 | Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status |
| Q33418642 | Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer |
| Q46471444 | Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer |
| Q57569731 | Re: Small Cell Lung Cancer Treated in Southeast Wales, Lester et al., Clin Oncol 2006;18:378–382 |
| Q47844950 | Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study |
| Q47784321 | Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. |
| Q53415548 | Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''. |
| Q56828390 | Revised U.K. guidelines for the management of cutaneous melanoma 2010 |
| Q56828394 | Revised UK guidelines for the management of cutaneous melanoma 2010 |
| Q55378086 | SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy. |
| Q90457340 | Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172) |
| Q92839836 | Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172) |
| Q34652628 | Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study |
| Q40503953 | Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase. |
| Q57569523 | Sequential immunotherapy regimens—expect the unexpected |
| Q36185018 | Sequential platinum-based chemotherapy-thoracic radiotherapy in early stage non-small cell lung cancer |
| Q57569717 | Small Cell Lung Cancer (SCLC); any progress? |
| Q57569821 | Small cell carcinoma of the cervix |
| Q46908104 | Sodium salicylate inhibits TNF-alpha-induced NF-kappaB activation, cell migration, invasion and ICAM-1 expression in human melanoma cells |
| Q35212678 | Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies |
| Q112568096 | Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism |
| Q89686121 | Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma |
| Q38850349 | Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma |
| Q35645254 | Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials |
| Q57818331 | Surrogate endpoints in advanced sarcoma trials: a meta-analysis |
| Q26829819 | Survival benefits from follow-up of patients with lung cancer: a systematic review and meta-analysis |
| Q90369153 | Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019 |
| Q38680472 | Survival of patients with advanced metastatic melanoma: The impact of novel therapies |
| Q38653551 | Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. |
| Q52577115 | Survival of patients with early invasive melanoma down-staged under the new 8th AJCC edition. |
| Q26996629 | Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma |
| Q37099104 | Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future? |
| Q38305465 | TNF-alpha increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes |
| Q57569714 | Tarceva in relapsed non-small cell lung cancer: experience from Northwest England |
| Q57569703 | Targeting angiogenesis in melanoma |
| Q55235076 | Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial. |
| Q57569791 | Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group |
| Q112293530 | The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival |
| Q44934727 | The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. |
| Q53835547 | The place of PD-1 inhibitors in melanoma management. |
| Q91323544 | The role for chemotherapy in the modern management of melanoma |
| Q57569574 | The role of chemotherapy in the modern management of melanoma |
| Q47735641 | The role of nivolumab in melanoma |
| Q37869608 | The role of positron emission tomography in management of small cell lung cancer |
| Q44476097 | The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit |
| Q33490442 | Therapy for small cell lung cancer using carboplatin, ifosfamide, etoposide (without dose reduction), mid-cycle vincristine with thoracic and cranial irradiation. |
| Q36228172 | Thoracic radiation therapy for limited-stage small-cell lung cancer: unanswered questions |
| Q36350401 | Thoracic radiotherapy for limited-stage small-cell lung cancer: controversies and future developments |
| Q47442582 | Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: a retrospective, longitudinal survey (MELODY study). |
| Q39384594 | Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study |
| Q47177555 | Unmet supportive care needs, health status and minimum costs in survivors of malignant melanoma |
| Q57569715 | Update on targeted therapies for small cell carcinoma of the lung |
| Q51046549 | Urgent treatment of patients with metastatic melanoma using Braf inhibitors in the absence of Braf mutation status. |
| Q33394319 | Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial |
| Q73548895 | VEDex (vincristine, epirubicin dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin's lymphoma |
| Q46319029 | Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study |
| Q57569600 | Vemurafenib-induced nonautoimmune haemolytic anaemia |
Search more.